Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 124,998 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $15.59, for a total transaction of $1,948,718.82. Following the completion of the transaction, the chief executive officer owned 2,584,243 shares of the company’s stock, valued at $40,288,348.37. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Adaptive Biotechnologies Stock Down 4.6%

Shares of Adaptive Biotechnologies stock opened at $15.96 on Friday. The company has a market cap of $2.44 billion, a P/E ratio of -29.56 and a beta of 2.18. The firm’s 50 day moving average price is $16.48 and its 200-day moving average price is $14.25. Adaptive Biotechnologies Corporation has a 52-week low of $5.97 and a 52-week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The company had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same period last year, the firm earned ($0.22) earnings per share. Adaptive Biotechnologies’s revenue was up 102.4% compared to the same quarter last year. As a group, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sound Income Strategies LLC purchased a new stake in shares of Adaptive Biotechnologies in the 3rd quarter valued at $30,000. Smartleaf Asset Management LLC boosted its holdings in Adaptive Biotechnologies by 593.5% in the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after purchasing an additional 3,371 shares during the last quarter. Caxton Associates LLP acquired a new stake in Adaptive Biotechnologies during the 1st quarter worth about $93,000. Teza Capital Management LLC purchased a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at about $118,000. Finally, Quadrant Capital Group LLC acquired a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at about $133,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. BTIG Research increased their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday. JPMorgan Chase & Co. lifted their target price on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Guggenheim assumed coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 30th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and a consensus target price of $17.11.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.